Download PDF
Thromb Haemost 1992; 67(02): 284
DOI: 10.1055/s-0038-1648429
Letters to the Editor
Schattauer GmbH Stuttgart

Increase in Fibrinolytic Activity after Erythropoietin Therapy

Jolanta Szewczuk
Department of Nephrology, Medical School, Zurawia 14, 15-540 Bialystok, Poland
,
Maria Mazerska
Department of Nephrology, Medical School, Zurawia 14, 15-540 Bialystok, Poland
,
Jacek Malyszko
Department of Nephrology, Medical School, Zurawia 14, 15-540 Bialystok, Poland
,
Marek Kalinowski
Department of Nephrology, Medical School, Zurawia 14, 15-540 Bialystok, Poland
,
Michal Mysliwiec
Department of Nephrology, Medical School, Zurawia 14, 15-540 Bialystok, Poland
› Author Affiliations
Further Information

Publication History

Received 17 June 1991

Accepted after revision 09 August 1991

Publication Date:
02 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints
 

  • References

  • 1 Casati C, Passerini P, Campise MR, Graziani G, Cesana B, Perisic M, Ponticelli C. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J 1987; 295: 1017-1020
    CrossrefPubMedSearch in Google Scholar
  • 2 Gordge MP, Leaker B, Patel A, Oviasu E, Cameron JS, Neild GH. Recombinant human erythropoietin shortens the uraemic bleeding time without causing intravascular haemostatis activation. Thromb Res 1990; 57: 171-182
    CrossrefPubMedSearch in Google Scholar
  • 3 Chmielewska JN, Wiman B. Determination of tissue plasminogen activator and its “fast” inhibitor in plasma. Clin Chem 1985; 32: 482-485
    PubMedSearch in Google Scholar